ArticleGastro hep advances2026
Bilirubin-Driven Phenotype Identifies Higher Mortality Risk in Severe Alcohol-Associated Hepatitis.
Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Among patients with severe alcohol-associated hepatitis (AH), the prognostic relevance of the dominant component of Maddrey's Discriminant Function (MDF) is unclear. Methods: We conducted a retrospective cohort study of adults with AH treated with corticosteroids at a US academic center (January 2016-December 2024). Using K-means clustering of the bilirubin and prothrombin time (PT) components of MDF, patients were classified into "PT-driven" vs "bilirubin-driven" phenotypes. The primary outcome was 90-day all-cause mortality. Inverse probability of treatment weighting-weighted Cox proportional hazards models were performed under an intention-to-treat framework, in which patients were not censored at liver transplantation. Secondary analyses used Fine-Gray competing risk models with liver transplantation as a competing event. Results: Among 212 patients, 56 (26.4%) died within 90 days. Despite a similar Model for End-Stage Liver Disease, the bilirubin-driven group (n = 100) had significantly lower MDF scores and less hepatic encephalopathy compared to the PT-driven group (n = 112). Nevertheless, in the inverse probability of treatment weighting-weighted Cox proportional hazards model, the bilirubin-driven phenotype was associated with higher 90-day mortality (hazard ratio, 2.06; 95% confidence interval, 1.05-4.04). Findings were consistent in the Fine-Gray competing risks model (subdistribution hazard ratio, 2.11; 95% confidence interval, 1.03-4.35). Conclusion: A bilirubin-dominant phenotype in severe AH was associated with significantly higher 90-day mortality, highlighting disease heterogeneity and suggesting potential value for risk stratification and for guiding future research on individualized care and optimal timing of liver transplant evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.